New music from Jun S (Ghost 9) coming today!

New music from Jun S (Ghost 9) coming today!

#KPop #KPopDailyPic #KPopNewMusic #SoloDebut #JunS

GHOST9 최준성, 디지털 싱글 ‘가짜사랑’으로 싱어송라이터 행보 #GHOST9 #최준성 #고스트나인 #가짜사랑 #JunS #디지털싱글 #싱어송라이터 #마루기획 보이그룹 GHOST9(고스트나인) 멤버 최준성(Jun S)이 솔로 디지털 싱글 ‘가짜사랑’을 통해 싱어송라이터 행보를 이어간다. 그는 그룹 활동과 병행하며 개인 음악 작업을 지속해온 만큼 이번 신곡에서 어떤 방향을 보여줄지 관심이 쏠린다. 최준성은 작사, 작곡, 편곡 전 과정에 직접 참여해 자신의 이름을 건 곡을 내놓는다. 제작 과정에서 주도적으로 목소리를 담아온 만큼, 솔로 아티스트로서 음악적 색채를 더욱 구체화하는 계기가 될 전망이다. 사랑의 진위보다 ‘누구와 함께하나’ 묻는 메시지, 직접 작사·작곡·편곡 참여. (사진=마루기획) ‘가짜사랑’은 사랑을 둘러싼 불신과 의심이 일상화된 시대를 출발점으로 삼는다. 진짜와 가짜를 가르는 기준에 매달리는 흐름 속에서, 정작 중요한 것은 감정의 진위보다 “누구와 함께하고 있는가”라는 질문을 던지는 내용이 핵심에 자리한다. 노랫말에서는 복잡해진 관계와 감정 속에서 사람 사이의 진심과 동행의 의미를 짚어낸다. 메시지에 맞춘 공감형 가사와 섬세한 감정 표현이 더해져 듣는 이들이 자신의 경험을 떠올릴 수 있는 곡으로 완성됐다. 이번 작업은 그가 솔로 아티스트로 가능성을 드러냈던 J-POP 디지털 싱글 ‘Melty Love’ 이후 이어지는 신보다. 당시 솔로 음원을 통해 개인 이름으로 무대를 넓힌 데 이어, 이번에는 한층 깊어진 정서를 전면에 내세운 셈이다. 그는 ‘Melty Love’ 이전에도 일본 현지에서 활동 중인 프로듀서 KO, 18세 비트메이커 BLOOD BOY와 함께한 ‘Super Type’으로 주목을 받은 바 있다. 이 곡은 높은 스트리밍 수와 틱톡 챌린지를 통해 반응을 확인하며 협업 작업의 가능성을 보여줬다. 이처럼 그룹 활동과 외부 프로듀서와의 협업, 솔로 프로젝트를 동시에 이어온 최준성은 자신만의 음악 세계를 점차 넓혀가고 있다. 싱어송라이터로서 직접 작업에 참여하는 방식이 앞으로의 활동에서도 하나의 흐름으로 자리하고 있다. 한편 최준성의 디지털 싱글 ‘가짜사랑’은 3월 17일 정오 각종 온라인 음원사이트에서 만날 수 있다.

GHOST9 최준성, 디지털 싱글 ‘가짜사랑’으로 싱어송라이터 행보 #GHOST9 #최준성 #고스트나인 #가짜사랑 #JunS #디지털싱글 #싱어송라이터 #마루기획

#COMEBACK | #JUNS (#GHOST9) anunciou o lançamento de seu novo seu single digital solo, intitulado “Fake Love”, para o dia 17 de março.

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference Jupiter Neurosciences (NASDAQ:JUNS) will present at the 3rd Annual DealFlow Discovery Conference on January 28-29, 2026 at The Borgata Hotel, Casino & Spa in Atlantic City, NJ.Christer Rosén, Chairman and CEO, will deliver a company presentation and is available for one-on-one investor meetings. Investors can request an investor pass at no cost to attend. More information about the company is available at the company website.

#JUNS Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

www.stocktitan.net/news/JUNS/jupiter-neuros...

Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6 Jupiter Neurosciences (NASDAQ: JUNS) invites investors to an exclusive live webinar on January 6, 2026 at 4:15 p.m. ET, hosted by RedChip Companies. Chairman and CEO Chister Rosén will review Jupiter's resveratrol-based platform JOTROL™, its differentiated bioavailability profile, and plans for an upcoming Phase 2a Parkinson’s disease trial.The presentation will also cover Jupiter’s dual-path strategy: early commercialization of the Nugevia™ longevity product line and the pharmaceutical development pathway, plus how recent financing supports execution. A live Q&A follows. Registration is free at the RedChip webinar page and questions can be pre-submitted to JUNS@redchip.com.

#JUNS Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6

www.stocktitan.net/news/JUNS/join-jupiter-n...

#JUNS Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum

www.stocktitan.net/news/JUNS/jupiter-neuros...

Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease Jupiter Neurosciences (NASDAQ:JUNS) announced that the FDA cleared its IND to initiate a Phase 2a clinical trial of JOTROL in Parkinson’s disease on November 5, 2025. The clearance enables enrollment for an exploratory Phase 2a study focused on safety and tolerability with secondary PK/PD and biomarker endpoints, and the company expects to begin enrollment in early 2026. Preclinical MPTP-model data showed improved motor endpoints; the company reports its micellar delivery achieves >9-fold higher bioavailability versus traditional resveratrol. Jupiter continues collaboration with Zina Biopharmaceuticals for protocol design and site selection.

#JUNS Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease

www.stocktitan.net/news/JUNS/jupiter-neuros...

Trade Alerts, Wednesday September 10, 2025 – Crystal Equity Research

Small-cap stock registering bullish MACD crossovers, Wed Sept 10th - #GLXG #SEER #QTTB #OBLG #NVNO #MAXN #LMFA #STRF #MIMI #HUHU #JUNS #AISP #BTBT #CAN - More: crystalequityresearch.com/trade-alerts... - #smallcap

$8 Trillion Market Opportunity: Jupiter Neurosciences Launches Clinical-Grade Longevity Supplements Jupiter Neurosciences introduces Nugevia supplement line using JOTROL platform with 9x bioavailability. Features GLO, PWR, and MND formulations, backed by Annika Sörenstam and Chris Webber.

#JUNS Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements

www.stocktitan.net/news/JUNS/jupiter-neuros...

5-Time NBA All-Star Chris Webber Partners with Jupiter Neurosciences for $8T Longevity Market Push NBA Hall of Famer Chris Webber joins Jupiter Neurosciences' Nugevia supplement line as brand ambassador. Products feature JOTROL delivery platform targeting $8T longevity market by 2030.

#JUNS Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

www.stocktitan.net/news/JUNS/jupiter-neuros...

Revolutionary Drug Delivery System Makes Resveratrol 9X More Effective, Targets Parkinson's and Alzheimer's Breakthrough JOTROL platform enhances resveratrol absorption, crosses blood-brain barrier for neurodegenerative diseases. See clinical trial results.

#JUNS Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

www.stocktitan.net/news/JUNS/jupiter-neuros...

Pharmaceutical Giant Disrupts $8T Beauty Market with Clinically-Proven Skin Health Breakthrough Revolutionary beauty supplement combines 9x better bioavailability with clinical validation. Targets cellular defense and collagen integrity. See the science behind it.

#JUNS Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science

www.stocktitan.net/news/JUNS/jupiter-neuros...

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador Jupiter Neurosciences (NASDAQ: JUNS) has announced golf legend Annika Sörenstam as the first brand ambassador for Nugevia, their new longevity supplement line. The partnership leverages Sörenstam's remarkable career of over 95 international tournament victories to promote Nugevia's science-backed formulations. The product line features three formulations - GLO, MND, and PWR - built on JOTROL, Jupiter's patented resveratrol-based micellar delivery platform known for enhanced bioavailability. The supplements target cellular resilience, cognitive function, and physical performance. This consumer product launch aligns with Jupiter's dual-path strategy, aiming to generate revenue from the growing longevity market (projected at $8 trillion by 2030) while supporting their clinical development programs.

#JUNS Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

www.stocktitan.net/news/JUNS/jupiter-neuros...

BREAKING NEWS: ( NASDAQ: #JUNS ) How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success

Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science Jupiter Neurosciences (NASDAQ: JUNS) has announced the launch of Nugevia™, a premium longevity and performance supplement line, set to debut in Q3 2025. The product line leverages Jupiter's proprietary JOTROL™ resveratrol-based platform technology, which demonstrated 9x improved bioavailability in clinical trials. The initial launch includes three formulations targeting mitochondrial support, mental clarity, and beauty enhancement, utilizing a direct-to-consumer model. This strategic move allows Jupiter to generate near-term revenue while maintaining its clinical pipeline development in CNS disorders. The company is positioning itself in the growing longevity market, projected to reach $8 trillion by 2030, while using a dual-path approach to create value through both consumer products and pharmaceutical development.

#JUNS Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science

www.stocktitan.net/news/JUNS/jupiter-neuros...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping up in trading, Wed May 28th - #NFGC #VVPR #SPRO #PAYS #OPAL #MBAV #JUNS #IMCC #HOLO #GASS #EVAX #CKPT #BROG #ACRS #VCSA #SOL #RZB #LVWR #HYLN #ANVS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Jupiter's Super-Resveratrol Targets Parkinson's Trial and $16.5M NIH Grant Enhanced resveratrol drug JOTROL advances to Phase 2a Parkinson's trial as Jupiter expands into longevity market. NIH grant decision pending. Full pipeline details inside.

#JUNS Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter

www.stocktitan.net/news/JUNS/jupiter-neuros...

Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? JUNS expands into the growing longevity market through Aquanova collaboration, creating new revenue streams while funding ongoing pharmaceutical trials.

#JUNS Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products

www.stocktitan.net/news/JUNS/jupiter-neuros...

Inside Jupiter's $50B Market Strategy: NIH Funding Secured, Phase 2 Trials Set for Revolutionary CNS Treatment Jupiter Neurosciences advances JOTROL platform with successful Phase 1 data, secures $1.76M NIH grant, and plans multiple Phase 2 trials. Consumer product launch set for 2025.

#JUNS Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

www.stocktitan.net/news/JUNS/jupiter-neuros...

Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients Jupiter Neurosciences teams with Catalent to produce JOTROL softgel capsules for Parkinson's trial, targeting $14B market with enhanced bioavailability resveratrol therapy.

#JUNS Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial

www.stocktitan.net/news/JUNS/jupiter-neuros...

Game-Changing Parkinson's Drug Enters Critical Trial Phase: New Hope for 10M Patients Jupiter partners with Zina Bio to accelerate JOTROL clinical trials for Parkinson's disease. Enhanced resveratrol formulation shows promise in reducing neurodegeneration markers.

#JUNS Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial

www.stocktitan.net/news/JUNS/jupiter-neuros...

#PP #Juns y #Vox la misma #mierda sos

¿Como se puede solucionar la situación actual a la que nos han llevado #pp #vox #psoe #sumar, #juns, #pnv?. Todo sube, hacen por beneficiar a multinacionales, perjudican al trabajador/ra y ellos mientras tanto se les costea todo, jubilaciones, seguros privados y sueldazos, 20 días y todo sigue igual

Jupiter Neurosciences Targets NLRP3 Inflammasome With JOTROL Platform for Alzheimer's Treatment Jupiter Neurosciences advances JOTROL platform targeting NLRP3 inflammasome, showing promise for neurodegenerative diseases with improved bioavailability over resveratrol.

#JUNS Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

www.stocktitan.net/news/JUNS/jupiter-neuros...

Fanart of Guardians of The Lamb by JUNS

Old Guardians of The Lamb fanart 🐑

#양의사수 #guardiansofthelamb #JUNS #fanart